Vosaroxin is a promising new agent in the treatment of AML, with the potential to improve CR rates in a high-risk group of patients with relapsed and refractory AML. However, higher CR rates have been associated with higher rates of treatment-related morbidity and mortality, especially in elderly/unfit patients. Maximising the potential of vosaroxin will therefore require the identification of patients most likely to benefit from vosaroxin-containing combination regimens.

Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S1. Bimodal expression of CD49d in an individual case of CLL. (A) Lymphocytes were gated based on forward and side scatter. (B) Single cells were gated based on forward Correspondence Methods Using data on key parameters in CLL from the Danish National Chronic Lymphocytic Leukaemia Registry, 9 we identified 1,309 patients with a diagnosis of CLL from 2008 to 2016 having a blood eosinophil count registered within 90 days of diagnosis. Eosinophilia was defined as a blood eosinophil count of >0Á5 9 10 9 /l, while a count of Correspondence

No abstract

The clinical significance of low-frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low-frequency del17p clones (<25%) were identified in 15/95 patients in the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. Patients with low del17p, without tumour protein p53 (TP53) mutation, had significantly longer progression-free survival and overall survival durations than patients with high del17p clones. In 11/15 cases with lowfrequency del17p, subclones solely with del17p or del13q were also noted. These data suggest that low-frequency del17p does not necessarily confer a poor outcome in CLL and challenges the notion of del13q as a founding event in CLL.